Skip to main content
Premium Trial:

Request an Annual Quote

DiaCarta Raises $45M in Series B Funding

NEW YORK (GenomeWeb) – DiaCarta said today that it has completed a Series B funding round, raising a total of $45 million. The second closing was led by Fortune Fountain Capital and included an investment from Good Health Capital.

DiaCarta Founder and CEO Aiguo Zhang said in a statement that the financing will support continued development of the company’s core XNA technology platform, and will support work to expand its diagnostic products for non-invasive early detection and monitoring of cancers. This will include establishing global clinical study programs in various areas, the commercial launch of the firm's liquid biopsy ColoScape assay for the detection of colorectal cancer, and the inception of new product development pipelines.

Funds raised will also help support future marketing applications to the US and China Food and Drug Administrations for relevant tests, Zhang said.


The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.